Review supports post-PCI use of dual antiplatelet therapy

07/10/2013 | Healio

Data review found dual antiplatelet therapy is the mainstay treatment for reducing cardiovascular risks after percutaneous coronary intervention, according to researchers from the University of Texas Southwestern Medical Center. The study, published in the Journal of the American Medical Association, recommended the low-dose aspirin component be continued indefinitely and a P2Y12 inhibitor should be prescribed for 12 months except in patients at high risk for bleeding.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA